| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
COVID-19 and liver diseases, what we know so far
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mohamed Elnaggar, Ahmed Abomhya, Ismail Elkhattib, Nabila Dawoud and Rajkumar Doshi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mohamed Elnaggar, MD, Staff Physician, Department of Internal Medicine, University of Nevada Reno school of Medicine, 1155 Mill Street, W-11
, Reno, NV 89052, United States. mohamed.elnaggar.md@gmail.com |
| Key Words |
COIVD-19; SARS-CoV-2; Liver diseases; Transaminases; Non alcoholic fatty liver; Hepatocellular carcinoma |
| Core Tip |
On March 12, 2020, the World Health Organization declared that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was a pandemic. SARS-CoV-2 is notorious for causing gastrointestinal and liver injuries. Liver injury mechanisms include SARS-CoV-2-induced hepatic steatosis, reactivation of pre-existing liver disease, mitochondrial dysfunction, cardiomyopathy with hepatic congestion, immune-mediated damage, hypoxic hepatitis, direct cytotoxicity, drug-induced liver injury, ischemic hepatitis, microthrombotic disease, and extrahepatic release of transaminases. The coronavirus disease 2019 (COVID-19) pandemic has various effects on pre-existing liver conditions that range from care disruptions, exacerbation of liver condition, and higher mortality rates. It is necessary to know the mechanisms of liver injury in COVID-19 disease, epidemiology, clinical presentations, diagnosis, and effects on pre-existing liver conditions. |
| Publish Date |
2022-04-30 05:08 |
| Citation |
Elnaggar M, Abomhya A, Elkhattib I, Dawoud N, Doshi R. COVID-19 and liver diseases, what we know so far. World J Clin Cases 2022; 10(13): 3969-3980 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i13/3969.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i13.3969 |
